TP53 and breast cancer: Linjawi et al. showed that patients with Bcl‐2 expression correlated with estrogen and progesterone receptors and p53 mutations showed poor survival in early breast cancer (Linjawi, Kontogiannea, Halwani, Edwardes, & Meterissian, 2004).